A phase I study to evaluate the safety and pharmacokinetics of R306465 in subjects with advanced solid malignancies
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2010
At a glance
- Drugs R 306465 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Johnson & Johnson
- 28 Apr 2010 Actual patient number (21) added as reported by ClinicalTrials.gov.
- 12 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
- 17 Feb 2006 New trial record.